Could lenalidomide boost chemo for tough AML?

NCT ID NCT03118466

Completed Disease control Sponsor: Massachusetts General Hospital Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial tested whether adding lenalidomide to standard MEC chemotherapy helps adults with relapsed or refractory acute myeloid leukemia (AML) achieve remission. 41 participants received the combination. The main goal was to see how many achieved complete remission. This study is completed, and results may show whether this approach is worth further testing.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: lenalidomide plus mitoxantrone, etoposide, and cytarabine (MEC chemotherapy)
What this could lead to: If successful, this combination could improve remission rates in patients with hard-to-treat AML, offering a bridge to more definitive treatments like transplant.
What could go wrong: This is a small, early-phase study (41 participants) without a comparison group. Results may not apply broadly, and the added lenalidomide could increase side effects like low blood counts or infections.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AML are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute myeloid leukemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

AML

Contacts and locations

Locations

Beth Israel Deaconess Medical Center

Boston, Massachusetts, 02215, United States
Dana Farber Cancer Institute

Boston, Massachusetts, 02062, United States
Massachusetts general Hospital

Boston, Massachusetts, 02215, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.